Management of type 2 diabetes mellitus: Defining the role of nateglinide

Disease Management and Health Outcomes

Volumn 10, Issue 6, 2002, Pages 363-383

  Carswell, Christopher I ^a   Culy, Christine R ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Diabetes mellitus; Disease management; Nateglinide; Review on treatment

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN DERIVATIVE; METFORMIN; NATEGLINIDE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ARTICLE; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DRUG TOLERABILITY; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; HYPOINSULINEMIA; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PREVALENCE; QUALITY CONTROL; QUALITY OF LIFE;

EID: 0036288644     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210060-00006     Document Type: Article

References (109)

1. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
2. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects
3. Standards of medical care for patients with diabetes mellitus
4. Therapeutic perspectives for type 2 diabetes mellitus: Molecular and clinical insights
5. Hyperinsulinaemia is a predictor of non-insulin-dependent diabetes mellitus
6. New directions in type 2 diabetes mellitus: An update of current oral antidiabetic therapy
7. New insulin secretagogues for the treatment of type 2 diabetes
8. Pharmacologic therapy for type 2 diabetes mellitus
9. Approaches to the management of postprandial hyperglycaemia
10. Matching treatment to pathophysiology in type 2 diabetes
11. Is insulin resistance the principal cause of type 2 diabetes?
12. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects
13. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: Evidence for multiple sites of insulin resistance
14. Lilly lecture 1994: The beta-cell in diabetes: From molecular genetics to clinical research
15. Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM
16. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes
17. Starlix health economics dossier
18. Undiagnosed NIDDM: Clinical and public health issues
19. Non-insulin-dependent diabetes mellitus in minorities in the United States
20. Ethnic differences in the glycemic response to exogenous insulin treatment in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM)
21. Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups
22. The use of sulphonylureas in the elderly
23. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr
24. Estimation of the prevalence of diagnosed diabetes from primary care and secondary care source data: Comparison of record linkage with capture-recapture analysis
25. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
26. Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. The San Antonio Heart study
27. Effects of aging on insulin secretion
28. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
29. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men
30. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians
31. Relationship between impaired glucose tolerance, non-insulin-dependent diabetes mellitus and obesity
32. Birth weight and non-insulin dependent diabetes: Thrifty genotype, thrifty phenotype, or surviving small baby genotype?
33. Major stressful life events in relation to prevalence of undetected type 2 diabetes: The Hoorn study
34. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus
35. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
36. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study
37. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
38. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
39. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
40. Hyperglycemia and microvascular and macrovascular disease in diabetes
41. The economic costs of non-insulin-dependent diabetes mellitus
42. The lifetime direct medical costs of managing diabetes and its complications in France
43. Lifetime costs of complications resulting from type 2 diabetes in the US
44. The effect of type 2 diabetes mellitus on health-related quality of life (HRQOL)
45. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37)
46. Impact of long-term complications on quality of life in patients with type 2 diabetes not using insulin
47. The quality of life of elderly diabetic patients
48. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus
49. Symptoms and well-being in relation to glycemic control in type II diabetes
50. Diabetes disease management improves care and may reduce long-term costs
51. Management of hypertension in patients with diabetes mellitus: Defining the role of lisinopril
52. Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus
53. Drug treatment of combined hyperlipidemia
54. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
55. Diabetes Mellitus: Disease management in a multispecialty group practice
56. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
57. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
58. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes
59. Treating obesity in type 2 diabetes. Calories, composition, and control
60. Impact of cigarette smoking on the incidence of type 2 diabetes mellitus in middle-aged Japanese men: The Osaka Health Survey
61. Smoking and diabetes
62. Management of type 2 diabetes: Finding a sensible pathway through the maze of available agents
63. Implications of the United Kingdom prospective diabetes study
64. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
65. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus
66. Multicenter, placebo-controlled trial comparing acarbose (BAY g5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus
67. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: A multicenter controlled clinical trial
68. The management of type 2 diabetes mellitus in the elderly patient
69. Rosiglitazone
70. Nateglinide improves glycaemic control when added to metformin monotherapy: Results of a randomized trial with type 2 diabetes patients
71. Nateglinide: A new member of the meglitinide family for postprandial glucose control in type 2 diabetes
72. American Diabetes Association: Clinical practice recommendations 1997
73. Diabetes mellitus disease management program: Outcomes and cost-effectiveness of diabetes treatment
74. Measuring outcomes of type 2 diabetes disease management program in an HMO setting
75. Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes
76. Mealtime glucose regulation with nateglinide in healthy volunteers: Comparison with repaglinide and placebo
77. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
78. Nateglinide is safe and efficacious in lowering postprandial blood glucose in type 2 diabetic patients with various degree of renal function
79. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
80. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
81. Nateglinide improves glycemic control alone and in combination with troglitazone in type 2 diabetes
82. Targeting postprandial hyperglycaemia in patients with type 2 diabetes: Nateglinide vs acarbose
83. Nateglinide has a low hypoglycemic potential in a missed-meal situation
84. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide
85. Hypoglycaemic admissions among diabetic patients in Soweto, South Africa
86. Compliance with, and understanding of, mealtime advice in patients with type 2 diabetes
87. Prandial glucose regulation with repaglinide: Its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes
88. The impact of diabetic complications on the quality of life of patients with type 2 diabetes
89. Diabetes nephropathy in the Netherlands: A cost effectiveness analysis of national clinical guidelines
90. Modeling the impact of a new oral anti-diabetic treatment on diabetes complication costs in France
91. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes
92. Evaluating the cost-effectiveness of clinical and public health measures
93. Clinical benefits and cost-offsets of combination therapy with nateglinide plus metformin versus metformin alone in diabetes in the Netherlands
94. Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
95. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes